The influence of public and private payers has increased dramatically and, consequently, a large percentage of pharma's top line revenues now flow from payers. Likewise, groups such as Accountable Care Organizations and Integrated Delivery Networks - while still relatively new - also are important to the biopharmaceutical industry because they affect the cost and utilization of prescriptions for large groups of patients.
Best Practices, LLC conducted this research to help organizations understand the drivers and decision-making of ACOs and IDNS. This study also highlights how companies are communicating and coordinating payer research efforts; how they are adjusting in a world increasingly focused on health outcomes and how companies' payer market research groups are using structure, roles and resources to meet payer market research needs.
SAMPLE KEY METRICS
- Study Overview
- Key Findings & Trends
- ACOs & IDNs are rising in importance
- Cross-functional collaboration and Communication are critical
- Optimizing Payer Research Structure, Roles & Resources
- Preparing to Compete in an outcomes-oriented world
SAMPLE KEY FINDINGS
- Importance rating for different payer groups and ACOs & IDNs over the next two years
- Market research approaches used to understand ACO and IDN decision-making
- Frequency of market research group meetings with internal stakeholders that interact with payers
- Anticipated staffing and investment growth/reduction for payer market research group over next two years
- Percentage of market research budget allocated to payer market research over the past year
- Structure of U.S. managed market research group
- Anticipated growth/reduction of resources for four comparative effectiveness research types during the next two years
Companies Are at Different Levels of Readiness on ACOs/IDNs:
- Nearly two-thirds of respondents are exploring opportunities to support ACOs
- Half study how ACOs and IDNs evaluate products in a therapeutic area
- Approaches for researching ACOs are varied and exist along a continuum from a wait-and-see approach to creating a dedicated function
The research employed a data gathering approach that reaps quantitative & qualitative data from 38 payer research leaders. More than half of the participants represent pharma or biotech companies, and another quarter come from medical device companies. Five selected participants were interviewed to add qualitative depth to the study.